ClinicalTrials.gg
CompletedNCT04893486Updated Aug 29, 2024

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

A Phase 2 interventional study of PTX-022 and Vehicle comparator in BCCs in Gorlin Syndrome Patients, sponsored by Palvella Therapeutics, Inc.. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Palvella Therapeutics, Inc. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Basal Cell Nevus Syndrome with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Basal Cell Nevus Syndrome · United States.

Enrollment
4th of 18
73 · median 35
Started
2021
the only one that year
Phase 2
10 of 20
none open now
Registered
19th of 20
by date
Lead sponsor
1 of 20
Palvella Therapeutics, Inc.

Among the 20 studies in Basal Cell Nevus Syndrome with a site in United States, this one is the 4th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is one of 10 in phase 2, and was the 19th registered.

Basal Cell Nevus Syndrome

35 studies on the registry are indexed under Basal Cell Nevus Syndrome; 4 are open to participants now.

Browse Basal Cell Nevus Syndrome studies →

Open to participants now

1 of the 20 studies in Basal Cell Nevus Syndrome with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Basal Cell Nevus Syndrome studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Basal Cell Nevus Syndrome with a site in United States, or all of them as a file.
02

Study summary

A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. This study will be conducted at multiple centers in the United States where participants with Gorlin Syndrome, also known as basal cell nevus syndrome, will be randomly placed into two groups; one group will receive the active topical gel, the other a topical vehicle gel, also know as placebo. Participants will apply this topical product to their face once a day for 6 months. The study will be looking at the number of new BCCs that develop on the faces of all the participants during this time.

03

Conditions studied

  • BCCs in Gorlin Syndrome Patients

Keywords

  • Gorlin Syndrome
  • Basal Cell Carcinoma
  • Nevoid basal cell carcinoma syndrome
  • Basal cell nevus syndrome BCNS
  • Gorlin Syndrome Alliance
  • Prevention
  • Topical
  • Sirolimus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults, 18 years or older
  • Meet diagnostic criteria for Gorlin Syndrome
  • Willing to avoid application of a non-study topical medication to the face (prescription or over the counter) during the study.
  • Willing to forego treatment of BCCs with anything other than the study medication except when the Investigator believes that delay of treatment of a BCC potentially might compromise the health of the subject. During the trial, the only allowed form of BCC treatment is surgical.
  • Participant will be encouraged to use their preferred sunscreen with a sun protector factor (SPF) of at least 30 daily

Key Exclusion Criteria:

  • Recently participated in a clinical trial evaluating an product for the treatment of BCCs or Gorlin Syndrome within 3 months prior to to starting study medication. Participant can start the study screening period prior to completing the 3 month washout.
  • Recently used topical or systemic (oral) treatment that might interfere with the evaluation of the study medication.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Active

    Drug: PTX-022

  • Placebo comparator
    Vehicle

    Drug: Vehicle comparator

Interventions

  • QTORIN 3.9 % Sirolimus Topical Gel

  • DrugVehicle comparator

    Vehicle comparator topical gel

06

What researchers measure

Primary outcomes

  1. Number of new biopsy confirmed BCCs that develop on the face compared between the active and vehicle treatment arms

    Time frame: Month 6

  2. Incidence of dermatological, treatment emergent adverse events after treatment with active

    Time frame: Month 6

Secondary outcomes

  1. Percentage of participants developing 2 or more new biopsy confirmed BCCs on the face.

    Time frame: Month 6

  2. Percentage of participants developing 1 or more new biopsy confirmed BCCs on the face.

    Time frame: Month 6

07

Study locations

16 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Burke Pharmaceuticals Research
    Hot Springs, Arkansas 71913, United States
  • Stanford Univeristy
    Palo Alto, California 94304, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Gwinett Clinical Research Center
    Snellville, Georgia 30078, United States
  • Clinical Coordinating Center (Minnesota)
    New Brighton, Minnesota 55112, United States
  • Mayo Clinic - Minnesota
    Rochester, Minnesota 55905, United States
  • St. Louis University
    Saint Louis, Missouri 63110, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • DermResearch Inc
    Austin, Texas 78759, United States
  • University of Utah
    Murray, Utah 84107, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
  • St. Pancras Clinical Research
    London, United Kingdom
  • Salford Foundation Trust
    Salford, M6 8HD, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Mar 2023, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2021
First posted
May 19, 2021
StartActual
May 6, 2021
Primary completionActual
Mar 13, 2023
CompletionActual
Mar 13, 2023
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04893486
Lead sponsor
Palvella Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 19, 2021
Start date
May 6, 2021
Primary completion
Mar 13, 2023
Completion
Mar 13, 2023
Last update
Aug 29, 2024

Study contacts

David Bickers, MD
study chair · Columbia University
Joyce Teng, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus Topical Gel PTX-022

Start the discussion